INSP (Inspire Medical Systems) 5-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INSP Inspire Medical Systems Inc INSP
57 GF Score
Price $63.04
GF Value $191.08
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Inspire Medical Systems 5-Year EBITDA Growth Rate?

Inspire Medical Systems INSP +2.89% 57 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates INSP with a GF Score™ of 57/100 and a GF Value™ of $191.08 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Inspire Medical Systems's EBITDA per Share for the three months ended in Jun. 2026 was $0.14.

During the past 12 months, Inspire Medical Systems's average EBITDA Per Share Growth Rate was 31.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Inspire Medical Systems was 34.60% per year. The lowest was -21.90% per year. And the median was -0.95% per year.


Inspire Medical Systems  (NYSE:INSP) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Inspire Medical Systems 5-Year EBITDA Growth Rate Related Terms


INSP vs AHCO, IART, CNMD: 5-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, Inspire Medical Systems's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inspire Medical Systems 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Inspire Medical Systems's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Inspire Medical Systems's 5-Year EBITDA Growth Rate falls into.


INSP
57GF Score
Inspire Medical Systems Inc INSP
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inspire Medical Systems 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Inspire Medical Systems (INSP) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Inspire Medical Systems and its competitors.
Is Inspire Medical Systems' 5-Year EBITDA Growth Rate too high?
Inspire Medical Systems' current 5-Year EBITDA Growth Rate is 0.00%. Overall, Inspire Medical Systems has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Inspire Medical Systems' 5-Year EBITDA Growth Rate compare to AHCO and IART?
Inspire Medical Systems' 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Inspire Medical Systems and its competitors. Inspire Medical Systems's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspire Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Inspire Medical Systems (INSP) is currently considered Significantly Undervalued. The stock's GF Value™ is $191.08, compared to a current price of $63.04 — trading 67% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. Inspire Medical Systems' overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Inspire Medical Systems (INSP), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inspire Medical Systems (INSP) Overvalued in 2026?

Based on GuruFocus' analysis, Inspire Medical Systems stock appears to be undervalued. The current stock price of $63.04 is trading 67% below its estimated GF Value™ of $191.08. GuruFocus considers Inspire Medical Systems to be Significantly Undervalued.

Key valuation signals for INSP:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: $191.08 vs. price of $63.04 (67% below fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the INSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inspire Medical Systems Business Description

Other Exchanges 2DR:Germany
Address 5500 Wayzata Boulevard, Suite 1600, Golden Valley, MN, USA, 55416
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
57GF Score

Get the complete analysis for INSP

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$63.04
Price
$191.08
GF Value